Gobernanza de riesgos de la nanomedicinael caso europeo

  1. Andoni Ibarra
  2. Hannot Rodríguez
Livre:
VII Conference of the Spanish Society for Logic, Methodology and Philosophy of Science: Santiago de Compostela, Spain, 18-20 July 2012
  1. Concha Martínez Vidal (dir. congr.)
  2. José L. Falguera López (dir. congr.)
  3. José M. Sagüillo (dir. congr.)
  4. Víctor M. Verdejo Aparicio (dir. congr.)
  5. Martín Pereira Fariña (dir. congr.)

Éditorial: Servicio de Publicaciones e Intercambio Científico ; Universidad de Santiago de Compostela

ISBN: 978-84-9887-939-1

Année de publication: 2012

Pages: 424-431

Congreso: Sociedad de Lógica, Metodología y Filosofía de la Ciencia en España. Congreso (7. 2012. Santiago de Compostela)

Type: Communication dans un congrès

DIALNET GOOGLE SCHOLAR lock_openMINERVA editor

Résumé

Nanomedicine is the application of nanotechnology to the study and improvement of human health, and a research area of high economic significance as well. But it also implies risks for human health and the environment, so the European Union claims to be committed to its “responsible development”. However, there are different opinions in the EU about how nanomedicine—and nanotechnology in general—should be regulated. This paper will analyze critically two of the more relevant opinions.

La source de données: Dialnet